Glenmark to launch generic Adderall

Glenmark is set to launch a generic version of Teva’s Adderall tablets in strengths ranging from 5 mg to 30 mg, with distribution set to begin in May 2025.

The company will launch dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets (mixed salts of a single entity amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.

[Read more: Glenmark releases generic Travatan Z]

Glenmark’s product is the generic of Teva Womens Health’s Adderall Tablets (5 mg to 30 mg.)

Adderall tablets, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg had a market value of roughly $421.7 million for the 12 months ending February 2025, per IQVIA.

[Read more: Glenmark debuts Olopatadine Hydrochloride Ophthalmic Solution OTC]

Commenting on the launch, Marc Kikuchi, president & business head, North America at Glenmark said, "Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States. Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch.”